Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 571 KB, PDF-dokument

  • Sonja Holm-Yildiz
  • Tina Dysgaard
  • Thomas Krag
  • Britt Stævnsbo Pedersen
  • Sebastian Rask Hamm
  • Laura Pérez-Alós
  • Mia Marie Pries-Heje
  • Rasmus Bo Hasselbalch
  • Kamille Fogh
  • Johannes Roth Madsen
  • Linda Maria Hilsted
  • Erik Sørensen
We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).
TidsskriftJournal of Neuroimmunology
Antal sider5
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This work was financially supported by UCB . The control program was financially supported by the Carlsberg Foundation ( CF20–476 0045 , granted to PG), the Novo Nordisk Foundation ( NFF205A0063505 and NNF20SA0064201 , granted to PG), and the Svend Andersen Research Foundation ( SARF2021 , granted to PG). The grant bodies were not involved in any part of the study design, data collection, data analysis, interpretation of the data or the writing of this manuscript.

Publisher Copyright:
© 2023 The Authors

ID: 374564945